Breaking News Instant updates and real-time market news.

JAZZ

Jazz Pharmaceuticals

$122.56

0.65 (0.53%)

07:33
10/05/16
10/05
07:33
10/05/16
07:33

Jazz Pharmaceuticals risk/reward favorable, says BMO Capital

BMO Capital analyst Gary Nachman said recent Jazz Pharmaceutical management meetings confirm his positive thesis and said risk/reward in shares is favorable at current levels. Nachman said management sounded very confident in the company's outlook and he remains optimistic that a favorable Xyrem settlement would lift a significant overhang on the stock and help unlock untapped value with the pipeline. The analyst reiterates his Outperform rating and $195 price target on shares.

JAZZ Jazz Pharmaceuticals
$122.56

0.65 (0.53%)

07/28/16
COWN
07/28/16
NO CHANGE
Target $190
COWN
Outperform
Cowen recommends continuing to add to Jazz positions after IPR decision
Cowen analyst Ken Cacciatore noted that he has long considered Jazz's 8,772,306 patent as the "most critical component protecting the Xyrem franchise" and he believes that Amneal being denied its request to institute an inter partes review of the patent provides additional comfort. The analyst, who thinks that this decision sets the stage for Jazz and the remaining generic challengers to reach a settlement, recommends investors continue adding to Jazz positions. Cacciatore has a $190 price target and Outperform rating on Jazz shares.
08/25/16
JANY
08/25/16
INITIATION
JANY
Neutral
Jazz Pharmaceuticals initiated with a Neutral at Janney Capital
Janney Capital analyst Ken Trbovich started Jazz Pharmaceuticals with a Neutral rating and $145 fair value estimate, saying that Xyrem faces challenges from both branded competition and generics and he expects muted growth until Vyxeos is approved and launched in the second half of the next fiscal year.
09/26/16
JPMS
09/26/16
NO CHANGE
Target $205
JPMS
Overweight
Jazz pullback creates attractive entry point, says JPMorgan
JPMorgan analyst Jessica Fye believes the recent selloff in shares of Jazz Pharmaceuticals creates an attractive entry point for investors with a greater than three month time horizon. The analyst sees a "strong probability of success" for the JZP-110 Phase III data in early 2017 and believes the company's acquisition of Celator should help reduce the reliance on Xyrem, particularly post-2020. Fye keeps an Overweight rating on Jazz with a $205 price target.
10/05/16
BMOC
10/05/16
NO CHANGE
Target $195
BMOC
Outperform
Jazz risk/reward 'very favorable' at current levels, says BMO Capital
After hosting meetings with management, BMO Capital analyst Gary Nachman views the risk/reward as "very favorable" for shares of Jazz Pharmaceuticals. The analyst remains optimistic that a favorable Xyrem settlement would "lift a significant overhang" on shares and "help unlock untapped value with the pipeline." He reiterates an Outperform rating on Jazz with a $195 price target.

TODAY'S FREE FLY STORIES

ABB

ABB

$28.07

-0.02 (-0.07%)

05:55
01/17/18
01/17
05:55
01/17/18
05:55
Downgrade
ABB rating change  »

ABB downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IFF

International Flavors

$152.54

-1.16 (-0.75%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Upgrade
International Flavors rating change  »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AEP

American Electric

$67.50

0.04 (0.06%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$116.64

-1.53 (-1.29%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Downgrade
PPG rating change  »

PPG downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

NBR

Nabors Industries

$8.23

0.04 (0.49%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Nabors Industries rating change  »

Nabors Industries resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ETH

Ethan Allen

$28.15

-0.5 (-1.75%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Ethan Allen rating change  »

Ethan Allen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QTS

QTS Realty Trust

$52.47

0.82 (1.59%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
QTS Realty Trust rating change  »

QTS Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$18.44

-0.03 (-0.16%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Upgrade
La Quinta rating change  »

La Quinta upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$47.60

1.02 (2.19%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Recommendations
Ascendis Pharma analyst commentary  »

Ascendis Pharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

ENR

Energizer

$59.11

7.49 (14.51%)

05:47
01/17/18
01/17
05:47
01/17/18
05:47
Downgrade
Energizer rating change  »

Energizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

ABB

ABB

$28.07

-0.02 (-0.07%)

05:46
01/17/18
01/17
05:46
01/17/18
05:46
Upgrade
ABB rating change  »

ABB upgraded to Hold from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Recommendations
Celgene, Juno Therapeutics analyst commentary  »

Jefferies believes $8B…

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

DF

Dean Foods

$11.28

0.01 (0.09%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Upgrade
Dean Foods rating change  »

Dean Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

05:44
01/17/18
01/17
05:44
01/17/18
05:44
Downgrade
Apple rating change  »

Apple downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

RGC

Regal Entertainment

$22.90

-0.07 (-0.30%)

05:43
01/17/18
01/17
05:43
01/17/18
05:43
Downgrade
Regal Entertainment rating change  »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PII

Polaris Industries

$127.90

-2.13 (-1.64%)

05:43
01/17/18
01/17
05:43
01/17/18
05:43
Upgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

DISH

Dish

$47.99

-1.49 (-3.01%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Downgrade
Dish rating change  »

Dish downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

LBTYA

Liberty Global

$36.56

-0.31 (-0.84%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Upgrade
Liberty Global rating change  »

Liberty Global upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IR

Ingersoll-Rand

$90.26

-0.84 (-0.92%)

, MIELY

Mitsubishi Electric

$36.44

0.035 (0.10%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Hot Stocks
Ingersoll-Rand, Mitsubishi Electric establish JV for ductless and VRF systems »

Ingersoll-Rand (IR) and…

IR

Ingersoll-Rand

$90.26

-0.84 (-0.92%)

MIELY

Mitsubishi Electric

$36.44

0.035 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Upgrade
8x8, Inc. rating change  »

8x8, Inc. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 25

    Jan

NVS

Novartis

$86.73

0.08 (0.09%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Hot Stocks
Novartis granted FDA priority review for Kymriah »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Feb

  • 16

    Feb

  • 23

    Apr

  • 17

    May

SKX

Skechers

$37.91

-0.64 (-1.66%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Recommendations
Skechers analyst commentary  »

Skechers price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$100.69

-0.18 (-0.18%)

05:36
01/17/18
01/17
05:36
01/17/18
05:36
Hot Stocks
Walmart launches opioid disposal solution »

In an effort to help curb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.